MIM
IKT icon

MetLife Investment Management’s Inhibikase Therapeutics IKT Stock Holding History

MetLife Investment Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Buy
+62,913
New +$112K ﹤0.01% 2516

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's IKT Position: Q1 2026 in Review

MetLife Investment Management opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 62,913 shares worth $106K. The stake represents ﹤0.01% of the portfolio and ranks #2516 among its holdings.

104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • MetLife Investment Management held 62,913 shares of Inhibikase Therapeutics worth $106K as of Q1 2026.
  • Inhibikase Therapeutics was a new MetLife Investment Management position in Q1 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2516 holding.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.